Amgen Uplizna
Zenas BioPharma Shares Plummet After Phase 3 INDIGO Trial for Obexelimab in IgG4-Related Disease Meets Endpoint but Falls Short of Expectations
Zenas BioPharma; obexelimab; Phase 3 INDIGO; IgG4-related disease; share plunge; Amgen Uplizna